<?xml version="1.0" encoding="UTF-8"?>
<p>The most efficient approach to the treatment of COVID-19 is to test whether existing antiviral drugs are effective. In previous betacoronavirus epidemics, several antiviral drugs, such as ribavirin, interferon, lopinavir-ritonavir, and darunavir/cobicistat (prezcobix) were tested, with some showing promising in vitro results [
 <xref rid="B53-pathogens-09-00231" ref-type="bibr">53</xref>]. Remdesivir, an adenosine analog used against RNA viruses (including SARS and MERS-CoV), was a candidate Ebola treatment with promising in vitro results but disappointing in vivo effects against Ebola [
 <xref rid="B54-pathogens-09-00231" ref-type="bibr">54</xref>,
 <xref rid="B55-pathogens-09-00231" ref-type="bibr">55</xref>]. There is currently in vitro evidence that remdesivir may be effective in controlling SARS-CoV-2 infection [
 <xref rid="B56-pathogens-09-00231" ref-type="bibr">56</xref>]. In fact, compassionate use of remdesivir was employed in the treatment of the first COVID-19 case in the United States, during a period of rapid clinical deterioration, and within one day there was dramatic improvement of the clinical condition [
 <xref rid="B57-pathogens-09-00231" ref-type="bibr">57</xref>]. Randomized double-blinded, placebo-controlled clinical trials are currently underway in China and USA to evaluate the efficacy of remdesivir and initial results are expected by the end of April 2020 [
 <xref rid="B58-pathogens-09-00231" ref-type="bibr">58</xref>,
 <xref rid="B59-pathogens-09-00231" ref-type="bibr">59</xref>].
</p>
